Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Guillaume Feugère"'
Autor:
Ruth Moulson, Guillaume Feugère, Tracy S. Moreira-Lucas, Florence Dequen, Jessica Weiss, Janet Smith, Christine Brezden-Masley
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 2172-2184 (2024)
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2−) advanced/metastatic breast cancer (ABC/MBC) in first line (1L), but little i
Externí odkaz:
https://doaj.org/article/16198dbde7934a8f8964bc4ddb4c567e
Autor:
Steven Soroka, Mohsen Agharazii, Sandra Donnelly, Louise Roy, Norman Muirhead, Serge Cournoyer, Martin MacKinnon, Neesh Pannu, Brendan Barrett, François Madore, Karthik Tennankore, Jo-Anne Wilson, Fiona Hilton, Nancy Sherman, Kevin Wolter, John Orazem, Guillaume Feugère
Publikováno v:
Canadian Journal of Kidney Health and Disease, Vol 5 (2018)
Background: Dalteparin sodium, a low-molecular-weight heparin, is indicated for prevention of clotting in the extracorporeal circuit during hemodialysis (HD). Product labeling recommends a fixed single-bolus dose of 5000 international units (IU) for
Externí odkaz:
https://doaj.org/article/7fac2000982d44c0bc21e745c5226394
Publikováno v:
Journal of Thrombosis and Thrombolysis
In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2343f004a2de48e0715ed05008d5cacb
http://europepmc.org/articles/PMC6476994
http://europepmc.org/articles/PMC6476994
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
George Dranitsaris,1 Lesley G Shane,2 Mark Crowther,3 Guillaume Feugere,4 Seth Woodruff2 1Health Economic and Outcomes Research, Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 2Pfizer Inc, New York, NY, USA; 3McMaster University, Hamilton, ON
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7209bb89afd5bb140d653e21d2ddf95e
https://www.dovepress.com/dalteparin-versus-vitamin-k-antagonists-for-the-prevention-of-recurren-peer-reviewed-article-CEOR
https://www.dovepress.com/dalteparin-versus-vitamin-k-antagonists-for-the-prevention-of-recurren-peer-reviewed-article-CEOR
Publikováno v:
Value in Health. 19:A154-A155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::913ff413c339d23df0f3ec8f7dae70cb
https://doi.org/10.1016/j.jval.2016.03.1616
https://doi.org/10.1016/j.jval.2016.03.1616
Autor:
Guillaume Feugère, François Madore, Serge H. Cournoyer, Fiona Hilton, Brendan J. Barrett, Martin MacKinnon, Norman Muirhead, John Orazem, Kevin Wolter, Mohsen Agharazii, Nancy Sherman, Jo-Anne Wilson, Louise Roy, Steven D. Soroka, Karthik K. Tennankore, Sandra Donnelly, Neesh Pannu
Publikováno v:
Canadian Journal of Kidney Health and Disease, Vol 5 (2018)
Canadian Journal of Kidney Health and Disease
Canadian Journal of Kidney Health and Disease
Dalteparin sodium, a low-molecular-weight heparin, is indicated for prevention of clotting in the extracorporeal circuit during hemodialysis (HD). Product labeling recommends a fixed single-bolus dose of 5000 international units (IU) for HD sessions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65c0affdfeacaf4753c42e7c297a4cb
https://doi.org/10.1177/2054358118809104
https://doi.org/10.1177/2054358118809104
Autor:
François Madore, Fiona Hilton, Brendan J. Barrett, Norman Muirhead, Jo-Anne Wilson, Martin MacKinnon, Nancy Sherman, Sandra Donnelly, Serge H. Cournoyer, Louise Roy, Steven D. Soroka, Guillaume Feugère, Kevin Wolter, Mohsen Agharazii, John Orazem, Neesh Pannu
Publikováno v:
Nephrology Dialysis Transplantation. 32:iii289-iii289
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::555a036b7b9f2396699f09a2a820d23c
https://doi.org/10.1093/ndt/gfx150.sp481
https://doi.org/10.1093/ndt/gfx150.sp481
Publikováno v:
Thrombosis research. 131(3)
Introduction Long term anticoagulant therapy is recommended for treatment and secondary prevention of venous thromboembolism in cancer patients. We assessed outpatient anticoagulants [warfarin, low molecular weight heparins (LMWHs), fondaparinux and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26247f08b541a344d96349eeda6c288d
https://pubmed.ncbi.nlm.nih.gov/23290095
https://pubmed.ncbi.nlm.nih.gov/23290095
Publikováno v:
Journal of Thrombosis and Thrombolysis
Venous thromboembolism (VTE) is a common and serious complication in patients with cancer; treatment guidelines recommend extended therapy of ≥6 months with low-molecular-weight heparin (LMWH) for treatment and prevention of recurrent VTE (rVTE) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534e5206f3a5ae47cbd58276fc554723